Average weight loss on tirzepatide: what the trial evidence actually shows

Why the average figure is only one part of the picture

When people look up average weight loss on tirzepatide, they usually want to know whether the medicine will work for them specifically. That's a fair instinct, but averages conceal a spread. In SURMOUNT-1, published in the New England Journal of Medicine, participants who reached the 15mg dose lost around 20–21% of body weight on average over 72 weeks. Some lost more. Some lost less. Starting BMI, metabolic factors, how well GI side effects were tolerated, and the lifestyle work done alongside the injection all pulled results in different directions.

The 5mg and 10mg doses showed lower averages (roughly 15% and 19% respectively) which matters because not every patient will reach the highest dose. Prescribers titrate up gradually, and some people stay at an intermediate dose long-term because it suits them better. If you want a feel for what early weeks look like, the picture in week 1 is often quite different from the 72-week endpoint.

One practical habit worth building: weigh yourself on the same day each week, at the same time of day, before eating or drinking. A single reading tells you very little; a four-week trend tells you much more. Bodyweight fluctuates by 1–3kg day to day from fluid alone, so a week of apparent stasis on the scales doesn't mean the medicine isn't working.

The factors that shift your result from the average

Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1, slowing gastric emptying and reducing appetite through both pathways. That dual mechanism is part of why its trial averages sit above those of single-pathway GLP-1 medicines. But mechanism alone doesn't determine your outcome. How quickly the medicine begins to work varies, and the biggest driver of long-term results is what happens in months three through twelve, not the first few weeks.

Protein intake matters more than most patients expect on this treatment, appetite falls sharply, and if total calories drop without enough protein, muscle mass can go with them, which slows metabolism over time. Strength activity compounds the benefit. Sleep quality, stress and certain medications can all moderate the response. None of this means results are unpredictable; it means they are more in your hands than an average figure suggests.

NICE's appraisal of tirzepatide notes that if less than 5% body weight has been lost after six months at the highest tolerated dose, continuing treatment should be reviewed. That threshold is useful context: meaningful response, for most people, is visible well before six months. For a broader overview of what to expect on tirzepatide, including the realistic timeline, our clinical team has written a detailed guide.

How tirzepatide compares to the other option available in the UK

The SURMOUNT-5 open-label trial (72 weeks, 751 adults with obesity and no diabetes) put tirzepatide directly alongside semaglutide 2.4mg, the active ingredient in Wegovy. Tirzepatide produced greater average weight loss. NICE's appraisal of tirzepatide (TA1026) references indirect comparisons that also favour tirzepatide, though the committee acknowledged the limitations of cross-trial comparisons when direct evidence is limited.

The gap narrows at higher semaglutide doses: the newer 7.2mg semaglutide maintenance option (approved by the MHRA in April 2026) reported around 20.7% average loss over 72 weeks in trials, approaching the tirzepatide 15mg figure. Which medicine is appropriate depends on your medical history, how you respond to treatment and your prescriber's clinical judgment, not purely on which average looks better on a comparison page. You can read more about tirzepatide (Mounjaro) as a treatment or explore the weight-loss treatments we offer to see where both fit.

For those thinking about weekly progress specifically, average weekly loss figures break the timeline into more manageable units than a 72-week endpoint.

What this means for deciding whether to start

The trial data gives you a credible range, not a guarantee. Roughly 20% at 15mg over 72 weeks is a real, clinically meaningful figure, one that represents the average of thousands of adults in a controlled programme with lifestyle support built in. Real-world results in private practice tend to cluster near that range when treatment is genuinely supervised, doses are titrated appropriately and patients stay engaged with the process.

What the average can't tell you is whether tirzepatide is clinically appropriate for you, which dose you're likely to reach, or how your own starting point will interact with the medicine. Those questions belong in a clinical consultation. Average weight loss on Mounjaro (the UK brand name) covers the same evidence through a slightly different lens if you're comparing across search results. The week-by-week breakdown is useful once you've decided to start and want a benchmark for your own progress.

If you'd like a prescriber to review whether tirzepatide is right for you, start a free consultation, a real clinician reads every submission the same day.